Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine

AbstractA 62-year-old woman who underwent surgery to treat pancreatic cancer provided written, informed consent to undergo adjuvant therapy with gemcitabine, tegafur, and uracil. However, this was stopped after only 14  days due to Grade 4 neutropenia. She was then started on vaccine therapy with Survivin 2B peptide (SVN-2B) including IFA and INF-α. Although metastatic lung tumors were identified and resected at 82 months after surgery, the patient has remained free of new or relapsed disease for 12 years ther eafter. Tetramer and ELISPOT assays revealed the continuous circulation of SVN-2B-restricted cytotoxic T-lymphocytes (CTLs) in her peripheral blood, and CTL clones had specific activity for SVN-2B at 12 years after surgery. The adverse effects of the peptide vaccination were tolerable and comprised low-grade headache, nausea, and fatigue. A prognosis beyond 10 years in the face of pancreatic cancer with distant metastasis is extremely rare. This experience might indicate the value of cancer vaccination therapy.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research

Related Links:

Zhi-Chao Hu1,2,3†, Zu-Cheng Luo1,2,3†, Bing-Jie Jiang1,2,3†, Xin Fu1,2,3, Jiang-Wei Xuan1,2,3, Xiao-Bin Li1,2,3, Yu-Jie Bian1,2,3, Wen-Fei Ni1,2,3* and Ji-Xin Xue1,2,3* 1Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China 2The Second School of Medicine, Wenzhou Medical University, Wenzhou, China 3Bone Research Institute, The Key Orthopaedic Laboratory of Zhejiang Province, Wenzhou, China Osteoarthritis (OA), defined as a long-term progressive joint disease, is characterized by cartilage impairment and ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
This report supports that the novel mutation of RNF139 p.Q650R probably serve as a key role in HBs progression. Introduction Central nervous system hemangioblastomas (HBs) are benign tumors which usually occur in cerebellum (1), and the pathogenesis of HBs is still unknown. According to the revised World Health Organization (WHO) classification of tumors of the nervous system published in 2000, HBs were classified to the tumors of uncertain histogenesis. The morphology code of the International Classification of Diseases for Oncology (ICD-O)is 9161/1, grade I. HBs are composed of mesenchymal cells and abundant capi...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
CONCLUSIONS: Dabrafenib + trametinib was well tolerated and demonstrated a high rate of durable responses in patients with heavily pretreated recurrent/refractory BRAF V600E-mutated HCL.DisclosuresKreitman: NIH: Patents &Royalties: Co-inventor on the NIH patent for Moxetumomab Pasudotox. Moreau: Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors ...
Source: Blood - Category: Hematology Authors: Tags: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies: Novel Therapies and Prognostic Assessment in Hairy Cell Leukemia and Indolent Non-Hodgkin Lymphoma Source Type: research
Conclusion.Motesanib (AMG 706) demonstrated a 4‐month PFS that met the per‐protocol definition of efficacy. Fatigue and hypertension were the most common toxicities, and few grade 3–4 toxicities were encountered. The progression‐free survival of 8.7 months in all NETs merits further study.
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Head and Neck Cancers, Chinese Edition, Clinical Trial Results Source Type: research
AbstractA 62-year-old woman who underwent surgery to treat pancreatic cancer provided written, informed consent to undergo adjuvant therapy with gemcitabine, tegafur, and uracil. However, this was stopped after only 14  days due to Grade 4 neutropenia. She was then started on vaccine therapy with Survivin 2B peptide (SVN-2B) including IFA and INF-α. Although metastatic lung tumors were identified and resected at 82 months after surgery, the patient has remained free of new or relapsed disease for 12 years ther eafter. Tetramer and ELISPOT assays revealed the continuous circulation of SVN-2B-restricted ...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
CONCLUSION: Motesanib (AMG 706) demonstrated a 4-month PFS that met the per-protocol definition of efficacy. Fatigue and hypertension were the most common toxicities, and few grade 3-4 toxicities were encountered. The progression-free survival of 8.7 months in all NETs merits further study. The Oncologist 2018. PMID: 29853660 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Discussion Flushing is usually thought of as a benign condition such as blushing, but can be quite irritating if it is frequent or persistent (i.e. menopausal hot flashes) or even pathologic (i.e. malignancy). “Flushing is a subjective and sensation of warmth that is accompanied by reddening of the skin anywhere on the body but favors the face, neck, and upper torso…. Flushing can be broadly divided into episodic or persistent. Episodic flashing is mediated by the release of endogenous vasoactive mediators or medications, while persistent flushing result in a fixed facial erythema with telangiectasias and cyan...
Source: PediatricEducation.org - Category: Pediatrics Authors: Tags: Uncategorized Source Type: news
The drug sends a message to a caregiver after the patient swallowed it. The doctor prescribes virtual reality treatments for migraines. Do you think it is science fiction? You are mistaken. Just let me familiarize you with the top 10 trends shaping the future of pharma. I gave a speech recently to an audience of professionals working in healthcare regulation for the invitation of the Consumer Healthcare Products Association in Washington. After the keynote, a guy raised his hand and asked me the following: how can a regulatory agency keep up with the speed of new technologies in pharma? I get a lot of questions like this o...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Future of Medicine Future of Pharma 3d printing artificial intelligence augmented reality digital health gc4 Innovation nanotechnology Personalized medicine pharmacies pharmacogenetics pharmacology virtual reality VR Source Type: blogs
Conclusions:Pancreatic cancer associated LMC is extremely rare. With increased systemic control, however, there may be increasing occurrence of LMC and/or parenchymal involvement. To date, as with LMC associated with other solid tumors, survival is poor.Study Supported by: Not applicableDisclosure: Dr. Perilla has nothing to disclose. Dr. Melian has nothing to disclose. Dr. Schneck has received research support from NIH (POINT, COSS, ARUBA, ALIAS, Lundbeck (DIAS4), TIMI-50 Consortium, and Local PI Multicenter Clincial trials
Source: Neurology - Category: Neurology Authors: Tags: Neuro-oncology: Brain and CNS Metastases Source Type: research
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Cancer Vaccines | Headache | Immunotherapy | Migraine | Pancreas | Pancreatic Cancer | Vaccines